SARS CoV-2 genetic jump to a new SARS CoV-3 pandemic: Let’s be prepared

Kelleni, Mina

doi:10.1016/j.jinf.2023.03.018

Cited by 3 publications

(5 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, Egypt has officially acknowledged EG.5 subvariant only in August 2023 the SARS CoV-2, and in December 2023, Egypt has similarly acknowledged BA.2.86 and its descendant JN.1, which are currently the dominating global ones. Importantly, SARS CoV-2 variants of interests and concern are being closely monitored, due to their highly evolved immune-evasive properties which can lead to a potential reclassification of their global COVID-19 morbidity and mortality impact [4].…”

Section: Introductionmentioning

confidence: 99%

Real-Life Practice of Kelleni’s Protocol in Treatment and Post Exposure Prophylaxis of SARS CoV-2 Omicron HV.1 and JN.1 Subvariants

Kelleni

2024

Preprint

View full text Add to dashboard Cite

This brief report discusses the ongoing real-world practice using nitazxoanide, NSAIDs and/or azithromycin (Kelleni’s protocol) to manage the evolving manifestations of SARS CoV-2 Omicron EG.5.1, its descendant HV.1 as well as BA.2.86 and its descendant JN.1 subvariants in Egypt. These subvariants are well-known for their highly evolved immune-evasive properties and the manifestations include some peculiar manifestations as persistent cough besides high fever in young children as well as persistent severe cough, high fever, change of voice and marked bone aches in high risk groups of adults. It’s suggested that the ongoing SARS CoV-2 evolution is continuing to mostly affect the high risk groups of patients, to some of whom we’ve also successfully prescribed nitazoxanide and/or NSAIDs for post-exposure prophylaxis of all household contacts. We also continue to recommend starting the immune-modulatory antiviral Kelleni’s protocol as soon as possible in the course of infection and adjusting it in a personalized manner to be more aggressive from the beginning for the high risk patients, at least until the currently encountered surge of infections subsides.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-Life Practice of Kelleni’s Protocol in Treatment and Post Exposure Prophylaxis of SARS CoV-2 Omicron HV.1 and JN.1 Subvariants

Kelleni

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…SARS CoV-2 evolution is ongoing while threatening to return the world to square one [1][2][3]. However, Africa has adopted early treatment approach and managed to avoid most of the burden of COVID-19 [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…Notably, Egypt has officially acknowledged EG.5 subvariant only in August 2023, and in December 2023, Egypt has similarly acknowledged BA.2.86 and its descendant JN.1, which are currently the dominating global ones. Importantly, SARS CoV-2 variants of interests and concern are being closely monitored, due to their highly evolved immune-evasive properties which can lead to a potential reclassification of their global COVID-19 morbidity and mortality impact [3].…”

Section: Introductionmentioning

confidence: 99%

Real-Life Practice of Kelleni’s Protocol in Treatment and Post Exposure Prophylaxis of SARS CoV-2 Omicron HV.1 and JN.1 Subvariants

Kelleni

2024

Preprint

View full text Add to dashboard Cite

This perspective discusses the ongoing real-world practice using nitazxoanide, NSAIDs and/or azithromycin (Kelleni’s protocol) to manage the evolving manifestations of SARS CoV-2 Omicron EG.5.1, its descendant HV.1 as well as BA.2.86 and its descendant JN.1 subvariants in Egypt. These subvariants are well-known for their highly evolved immune-evasive properties and the manifestations include some peculiar manifestations as persistent cough besides high fever in young children as well as high fever, persistent severe cough, change of voice, loss of taste and smell, epigastric pain, nausea, vomiting, diarrhea, generalized malaise and marked bone aches in adults including the high risk groups. It’s suggested that the ongoing SARS CoV-2 evolution is continuing to mostly affect the high risk groups of patients, to some of whom we’ve also successfully prescribed nitazoxanide and/or NSAIDs for post-exposure prophylaxis of all household contacts. We also continue to recommend starting the immune-modulatory antiviral Kelleni’s protocol as soon as possible in the course of infection and adjusting it in a personalized manner to be more aggressive from the beginning for the high risk patients, at least until the currently encountered surge of infections subsides.

show abstract

“…Notably, I have recently called the global health care authorities for aborting the remaining COVID-19 restrictions/mandates (Kelleni 2023a , d ) and emailed top officials in the US FDA and the WHO informing about this call. Fortunately, we soon witnessed a positive response represented by the subsequent official termination of the American and the World Health Organization COVID-19 public health emergency status in April and May 2023, respectively.…”

mentioning

confidence: 99%

“…However, in our clinical practice, we continue to witness the ongoing evolutionary changing tropism of SARS CoV-2 omicron subvariants (Kelleni 2023c ) including the recent XBB.1.16 subvariant, currently known with its evolved enhanced tropism toward the conjunctival epithelia especially in the pediatric population. Moreover, many international experts anticipate a new surge of cases coming from one of the currently evolving or a yet to be discovered SARS CoV-2 (sub)variants and some even warned that this could be soon witnessed, even sooner than what was previously expected (Kelleni 2023d ).…”

mentioning

confidence: 99%

The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one

Kelleni

2023

Inflammopharmacol

Self Cite

View full text Add to dashboard Cite

For over 3.5 years, SARS CoV-2 is continuing to evolve threatening to return all and any improvement the world has made into square one. In this clinically oriented systematic review and perspective, the author explains how the best current medical evidence is strongly supporting the use of the low cost, widely available and very safe nitazoxanide in early management of COVID-19, debates the relevant theoretical studies that negated or doubted this benefit, and suggests an African roadmap to preempt the worst-case scenario if or when a new SARS CoV-2 (sub) variant or even a new respiratory virus causes a new global surge of morbidity and mortality. Kelleni’s protocol, including nitazoxanide as an integral component, is continuing to perfectly save lives of patients infected with many viruses, including SARS CoV-2 and the author stresses that respiratory RNA viruses are best managed with early pharmacological treatment. Broad-spectrum antimicrobials as nitazoxanide and azithromycin together with other therapeutics as non-steroidal anti-inflammatory drugs and the antihistaminic loratadine should be considered first to personalize the clinical management of COVID-19 and selected other alarming viral infections.

show abstract

SARS CoV-2 genetic jump to a new SARS CoV-3 pandemic: Let’s be prepared

Cited by 3 publications

References 11 publications

Real-Life Practice of Kelleni’s Protocol in Treatment and Post Exposure Prophylaxis of SARS CoV-2 Omicron HV.1 and JN.1 Subvariants

Real-Life Practice of Kelleni’s Protocol in Treatment and Post Exposure Prophylaxis of SARS CoV-2 Omicron HV.1 and JN.1 Subvariants

Real-Life Practice of Kelleni’s Protocol in Treatment and Post Exposure Prophylaxis of SARS CoV-2 Omicron HV.1 and JN.1 Subvariants

The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one

Contact Info

Product

Resources

About